IRL1117
Core PD symptoms (once-daily oral)
PreclinicalPending Phase I
Key Facts
Indication
Core PD symptoms (once-daily oral)
Phase
Preclinical
Status
Pending Phase I
Company
About IRLAB Therapeutics
IRLAB Therapeutics is dedicated to transforming the lives of patients with Parkinson's disease through its innovative, data-driven discovery platform and focused clinical pipeline. The company's proprietary Integrative Screening Process (ISP) accelerates and de-risks drug discovery, having generated multiple clinical-stage candidates. With a Phase III-ready asset for dyskinesia and a strategic focus on the high-growth Parkinson's market, IRLAB is positioned to address significant unmet medical needs and create substantial value.
View full company profile